VIDEO: Ibrutinib before apheresis requires further study, may improve CAR-T manufacturing
Click Here to Manage Email Alerts
New data suggest ibrutinib may be able to improve CAR T-cell production when administered before apheresis, according to a presentation at the ASH Annual Meeting and Exposition.
“We found that early use of ibrutinib as a lead into apheresis actually led to a phenotype of the CAR T-cell product that was more sort of central memory and more stem-like product that expanded better within the patients. It suggests ... the use of ibrutinib in DLBCL lymphoma patients can improve the function of CAR T-cells if given before apheresis,” Frederick Locke, MD, co-leader of the Immunology Program at Moffitt Cancer Center, said in a Healio interview.
Collapse
Chavez, RG et al. Abstract 1200. Presented at: ASH Annual Meeting and Exposition (virtual meeting); Dec. 5-8, 2020.
Read more about
Click Here to Manage Email Alerts